Pharmako Biotechnologies’ PlexoZome Curcumin found to support respiratory recovery
Pharmako Biotechnologies’ reveals its PlexoZome Curcumin has positive effects on A549 human lung adenocarcinoma cells, according to a newly published study. The company emphasizes that the findings may be a foundation to develop a curcumin-based nanoformulation as a therapy for NSCLC (non-small cell lung cancer).
“PlexoZome, advanced liposomal curcumin formulation, shows immense promise in managing inflammation, combating oxidative stress and, most notably, addressing key characteristics of lung cancer,” says Dr. Kam Dua, lead of the Drug Delivery Node Respiratory Pharmaceutical Research Team at the Graduate School of Health at the University of Technology Sydney, Australia..
“Its unique delivery system enhances curcumin’s bioavailability, maximizing its therapeutic impact on lung health. We are enthusiastic about our research partnership with Pharmako Biotechnologies and the potential this collaboration holds in making a meaningful difference in managing and treating respiratory conditions.”
Phytochemicals such as curcumin are well-known for their potential to promote a healthy inflammatory response and for their antioxidant support, but such ingredients’ poor solubility and bioavailability have also been established.
Pharmako Biotechnologies argues that its encapsulation of curcumin in nanoparticle-based delivery systems such as liposomes helps overcome such limitations.
Reducing cancer marker proteins
The study, published in Science Direct, determines that curcumin-loaded liposomes like PlexoZome have positive effects on the A549 human lung adenocarcinoma cells.
It showcases how liposomal curcumin may functionally suppress the proliferation, migration and colony formation of such cells while also reducing the expression of multiple cancer marker proteins.
George Kokkinis, CEO and founder of Pharmako Biotechnologies, comments: “There are millions of people around the globe that are affected by this common, horrible disease.”
“Couple this with over 700 published studies on curcumin and its properties against lung cancer. It makes sense to explore advanced delivery technologies, namely liposomes, to accurately and precisely deliver this molecule. This study paves the way for further investigation of curcumin’s ability to fight lung cancer in humans.”
